Profile: Cell Therapeutics, Inc. deals with cancer drugs. Our cancer drug development pipeline includes a biologically enhanced taxane, a new compound designed to treat cancers normally treated with anthracyclines, and a DNA minor groove binding agent, each of which has the potential to treat a variety of cancer types. Our development pipeline comprises of Pixantrone, Opaxio™, and Brostallicin.